Holen Sie sich die Stockscreener-App
6.53
3.65%
0.23
Vorhandelsmarkt:
6.26
-0.27
-4.13%
Schlusskurs vom Vortag:
$6.30
Offen:
$6.38
24-Stunden-Volumen:
794.09K
Relative Volume:
0.55
Marktkapitalisierung:
$403.24M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$-43.51M
KGV:
-4.8677
EPS:
-1.3415
Netto-Cashflow:
$-39.73M
1W Leistung:
+0.46%
1M Leistung:
-5.36%
6M Leistung:
+4.15%
1J Leistung:
-5.09%
1-Tages-Spanne:
$6.3126
$6.58
1-Wochen-Bereich:
$6.24
$6.7101
52-Wochen-Spanne:
$4.50
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
6.53 | 399.53M | 2.00M | -43.51M | -39.73M | -1.3415 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2026-02-03 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-11 | Eingeleitet | Wedbush | Outperform |
| 2025-08-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-12-06 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Herabstufung | Goldman | Buy → Neutral |
| 2024-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-25 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-08 | Eingeleitet | Goldman | Buy |
| 2023-08-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-08 | Eingeleitet | Piper Sandler | Overweight |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Sagimet Biosciences (SGMT) director receives 39,567 stock options grant - Stock Titan
Sagimet Biosciences (SGMT) director receives stock option grant for 39,567 shares - Stock Titan
Director at Sagimet Biosciences (NASDAQ: SGMT) receives 39,567 stock options - Stock Titan
Sagimet Biosciences (SGMT) director receives 39,567 stock options at $6.48 - Stock Titan
Sagimet Biosciences (SGMT) grants director Kemble George 39,567 stock options - Stock Titan
Director Anne Phillips receives 39,567 Sagimet (SGMT) stock options at $6.48 strike - Stock Titan
Sagimet Biosciences Announces Board Changes and Director Elections - TipRanks
Tim Walbert resigns from Sagimet's board - TradingView
Sagimet Biosciences (SGMT) director resigns as shareholders elect Board, ratify KPMG - Stock Titan
Sagimet Biosciences Inc. Announces Resignation of Tim Walbert as Member of the Board of Directors, Effective as of June 12, 2026 - marketscreener.com
Certain Restricted Stock Units of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2026. - marketscreener.com
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher - MSN
Sagimet Biosciences Grants New Performance-Based Executive Equity Awards - TipRanks
[8-K] Sagimet Biosciences Inc. Reports Material Event - Stock Titan
Sagimet Biosciences (SGMT) Slides 1.99% as Stock Approaches Key Support ZoneCalendar Spread Trade - newsline.com
Sagimet Biosciences (SGMT) grants CEO options on 300,000 shares - Stock Titan
Sagimet (SGMT) CFO receives 50,000 options at $7.27 exercise price - Stock Titan
Sagimet Biosciences Inc. (SGMT) is a great momentum stock: Should you buy? - MSN
SGMT Stock Price, Quote & Chart | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH - Caledonian Record
Sagimet Biosciences Presents Two Posters At EASL 2026 On Denifanstat/Resmetirom Combination In MASH - marketscreener.com
Sagimet Biosciences (SGMT) Inches Higher as Stock Tests Key Resistance at $7.48Adaptive Moving Average - thelegaladvocate.com
Sagimet Biosciences (SGMT) Edges Higher as Clinical Momentum BuildsSentiment Divergence - thelegaladvocate.com
Sagimet Biosciences (SGMT) Gains 1.29% as Shares Test Key Resistance LevelPut Flow Alert - newsline.com
Sagimet Biosciences Inc. Q1 2026 Earnings: Narrowed Loss Beats Expectations as Clinical Pipeline Advances - newsline.com
SGMT Technical Analysis | Trend, Signals & Chart Patterns | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Why Are Analysts So Bullish on Sagimet Biosciences (SGMT) - Kavout
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade - MSN
SGMT Maintained by Citizens -- Price Target Lowered to $12 - GuruFocus
Citizens cuts Sagimet Biosciences stock price target on valuation By Investing.com - Investing.com Nigeria
Sagimet Biosciences Is Maintained at Market Outperform by Citizens - Moomoo
Citizens JMP Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Citizens cuts Sagimet Biosciences stock price target on valuation - Investing.com
Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results - MSN
Sagimet Biosciences (SGMT) price target increased by 15.00% to 29.86 - MSN
Number of shareholders of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Sagimet Biosciences (SGMT) CMO receives 264,759 stock options at $6.44 strike - Stock Titan
Sagimet Biosciences (SGMT) files Form 3 identifying Chief Medical Officer Andreas Grauer - Stock Titan
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat (NASDAQ:SGMT) - Seeking Alpha
Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target - TipRanks
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - GlobeNewswire
Biotech Sagimet to give fireside chat at NASDAQ investor event - Stock Titan
Sagimet Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Sagimet Biosciences reports first quarter 2026 financial results and provides corporate updates - marketscreener.com
Sagimet Biosciences Reports First Quarter 2026 Financial Results And Provides Corporate Updates - TradingView
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sagimet Biosciences Inc-Aktie (SGMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chauche Thierry | Chief Financial Officer |
Feb 10 '26 |
Sale |
5.36 |
1,312 |
7,033 |
15,688 |
| Martins Eduardo Bruno | Chief Medical Officer |
Feb 10 '26 |
Sale |
5.36 |
3,640 |
19,511 |
103,296 |
| Rozek Elizabeth | Chief Legal & Admin. Officer |
Feb 10 '26 |
Sale |
5.36 |
2,622 |
14,054 |
190,959 |
| Kemble George | Executive Chairman |
Nov 20 '25 |
Sale |
7.69 |
37,688 |
289,979 |
81,005 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):